Literature DB >> 16848721

Regulation of multidrug resistance by pro-inflammatory cytokines.

Emmanuel A Ho1, Micheline Piquette-Miller.   

Abstract

Various mechanisms have been implicated in the development of resistance of cancer cells to chemotherapy. Multidrug resistance (MDR) is a phenomenon in which cancer cells are resistant to the cytotoxic effects of various structurally and mechanistically unrelated chemotherapeutic agents. One major mechanism by which this occurs is through the over-expression of ATP-dependent drug efflux transporters such as the P-glycoprotein (PGP) and multidrug resistance-associated protein (MRP). Regulation of MDR can occur at many levels including transcriptional, mRNA, protein and post-translational. In recent years it has been demonstrated that alterations in the expression and activity of the MDR transporters are seen in numerous tissues during an inflammatory response. An acute inflammatory response is associated with many conditions including infection, injury, hypoxia and stress and is known to result in the induction of several pro-inflammatory cytokines. Whether the function of cytokines can be harnessed in overcoming drug resistance of tumors has yet to be examined and explored. In this review, we will focus on the various studies investigating the regulation of MDR during an inflammatory response, in particular by cytokines. The mediators and pathways involved as well as the possible mechanisms of MDR regulation will be discussed. It is hoped that by understanding the clinical importance of inflammatory mediators in MDR, new doors will open and future insights will lead to the development of novel immunotherapeutics for the treatment of cancer.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16848721     DOI: 10.2174/156800906777441753

Source DB:  PubMed          Journal:  Curr Cancer Drug Targets        ISSN: 1568-0096            Impact factor:   3.428


  15 in total

1.  Binary and ternary combinations of anti-HIV protease inhibitors: effect on gene expression and functional activity of CYP3A4 and efflux transporters.

Authors:  Deep Kwatra; Aswani Dutt Vadlapudi; Ramya Krishna Vadlapatla; Varun Khurana; Dhananjay Pal; Ashim K Mitra
Journal:  Drug Metabol Drug Interact       Date:  2014

Review 2.  Modulation of P-glycoprotein at the blood-brain barrier: opportunities to improve central nervous system pharmacotherapy.

Authors:  David S Miller; Björn Bauer; Anika M S Hartz
Journal:  Pharmacol Rev       Date:  2008-06-17       Impact factor: 25.468

3.  Effect of prostaglandin E2 on multidrug resistance transporters in human placental cells.

Authors:  Clifford W Mason; Gene T Lee; Yafeng Dong; Helen Zhou; Lily He; Carl P Weiner
Journal:  Drug Metab Dispos       Date:  2014-09-26       Impact factor: 3.922

4.  The human P-glycoprotein transporter enhances the type I interferon response to Listeria monocytogenes infection.

Authors:  Nadejda Sigal; Millie Kaplan Zeevi; Shiri Weinstein; Dan Peer; Anat A Herskovits
Journal:  Infect Immun       Date:  2015-03-30       Impact factor: 3.441

5.  Pro-inflammatory cytokines interleukin-1 beta, interleukin 6, and tumor necrosis factor-alpha alter the expression and function of ABCG2 in cervix and gastric cancer cells.

Authors:  Fatemeh Mosaffa; Fatemeh Kalalinia; Herman Lage; Jalil Tavakol Afshari; Javad Behravan
Journal:  Mol Cell Biochem       Date:  2011-12-23       Impact factor: 3.396

Review 6.  Oxidative stress, inflammation, and cancer: how are they linked?

Authors:  Simone Reuter; Subash C Gupta; Madan M Chaturvedi; Bharat B Aggarwal
Journal:  Free Radic Biol Med       Date:  2010-09-16       Impact factor: 7.376

7.  Inhibition of p38 MAPK diminishes doxorubicin-induced drug resistance associated with P-glycoprotein in human leukemia K562 cells.

Authors:  Yinghui Chen; Yongbo Zhao; Cuicui Wang; Xia Xiao; Xiaoyong Zhou; Guoxiong Xu
Journal:  Med Sci Monit       Date:  2012-10

8.  Methylnaltrexone in the treatment of opioid-induced constipation.

Authors:  Beverley Greenwood-Van Meerveld; Kelly M Standifer
Journal:  Clin Exp Gastroenterol       Date:  2008-12-14

9.  Oligo-Fucoidan prevents IL-6 and CCL2 production and cooperates with p53 to suppress ATM signaling and tumor progression.

Authors:  Li-Mei Chen; Po-Yen Liu; Yen-An Chen; Hong-Yu Tseng; Pei-Chun Shen; Pai-An Hwang; Hsin-Ling Hsu
Journal:  Sci Rep       Date:  2017-09-19       Impact factor: 4.379

10.  Association of STAT-3 rs1053004 and VDR rs11574077 With FOLFIRI-Related Gastrointestinal Toxicity in Metastatic Colorectal Cancer Patients.

Authors:  Elena De Mattia; Erika Cecchin; Marcella Montico; Adrien Labriet; Chantal Guillemette; Eva Dreussi; Rossana Roncato; Alessia Bignucolo; Angela Buonadonna; Mario D'Andrea; Luigi Coppola; Sara Lonardi; Eric Lévesque; Derek Jonker; Félix Couture; Giuseppe Toffoli
Journal:  Front Pharmacol       Date:  2018-04-13       Impact factor: 5.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.